| 摘要 |
The invention features transgenically produced mutants of Antithrombin III, e.g., transgenically produced mutants of ATIII having enhanced antiangiogenic activity. The invention also features methods of making mutants of ATIII, and transgenic organisms which express a mutated ATIII. |
